Skye C. Mayo, M.D., M.P.H., FACS
- Associate Professor of Surgery, Division of Surgical Oncology, School of Medicine
- Director of Hepatic Arterial Infusion for Advanced Liver Malignancies, OHSU Knight Cancer Institute, School of Medicine
Biography
Dr. Skye Mayo is board certified in both Complex General Surgical Oncology and in General Surgery. His clinical practice serves patients with tumors of the liver, bile ducts, and pancreas. He also treats patients with gall bladder cancer, cancers of the stomach and digestive system, and retroperitoneal sarcomas. His research focuses on helping patients with cancers that have spread to or arise in the liver, such as colorectal cancer and intrahepatic cholangiocarcinoma.
Dr. Mayo’s family settled in Southeastern Oregon in the 1860s and established a cattle ranch. He was born in Burns and then moved to Central Oregon. After graduating from Stanford University he returned to Oregon for medical school combined with a Masters degree with public health in the epidemiology and biostatistics track. During his surgical residency at Johns Hopkins his clinical and research work focused on the treatment of patients with pancreatic and liver cancers. He completed a research fellowship in Cancer Immunology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins investigating the role of immune therapy in patients with metastatic liver disease. His surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York was focused in advanced Hepatopancreatobiliary Surgery where he was also certified to perform robotic cancer operations.
He is a member of a talented team of surgeons and oncologists at OHSU where he uses his experience and research to help advance the treatment of patients with cancers of the liver, bile ducts, and pancreas. He is a member of the OHSU Knight Cancer Institute and of the Southwest Oncology Group, which offers patients the latest in cancer care through participation in clinical trials. His research at OHSU involves using hepatic arterial regional therapy for patients with liver and bile duct cancers and investigating how to harness the immune system to fight cancer. Specifically, his research efforts are directed toward the early detection of recurrent cancer and monitoring responses to treatment in patients with colorectal cancer metastatic to the liver.
Dr. Mayo views it as a privilege to work with patients, their families, and primary care doctors to develop the best treatment plans. He is dedicated to offering the highest quality of service. He looks forward to working with other cancer specialists to help give his patients the most options and the best possible outcome.
Education and training
-
Degrees
- M.D., 2006, OHSU
- M.P.H., 2006, OHSU School of Public Health and Preventive Medicine
-
Residency
- General Surgery, The Johns Hopkins Hospital, Baltimore, MD, 2006-2013
-
Fellowship
- Cancer Immunology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical Institutions, Baltimore, MD, 2009-2011
- Complex General Surgical Oncology, Hepatopancreatobiliary Focus, Memorial Sloan-Kettering Cancer Center, New York, NY, 2013-2015
-
Certifications
- American Board of Surgery, General Surgery, 2013
- American Board of Surgery, Complex General Surgical Oncology, 2016
Memberships and associations:
- Society of Surgical Oncology (SSO)
- Americas Hepato Pancreato Biliary Association (AHPBA)
- American Society of Clinical Oncology (ASCO)
- Connective Tissue Oncology Society (CTOS, Sarcoma)
- American Association of Cancer Research (AACR)
- Johns Hopkins Surgery, Old Hands Club
- American College of Surgeons
- North Pacific Surgical Association
- Portland Surgical Society
- Mackenzie Surgical Society
- Alpha Omega Alpha (AOA) Medical Honor Society
- SWOG (Southwest Oncology Group) Surgery and Gastrointestinal Oncology Committee Member
- Trans Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG), Member
- International Cholangiocarcinoma Research Network, Surgical Oncology Committee (ICRN)
Areas of interest
- Early Detection of cancer recurrence
- Liver-directed therapies for metastatic and primary liver cancers
- Early phase clinical trial development in hepatopancreatobiliary oncology
- Surgical management of giant retroperitoneal sarcoma
- Risk factors for developing intrahepatic cholangiocarcinoma
- Cancer immunology
Additional information
Publications
Elsevier pure profilePublications
Adjuvant imatinib in high-risk resected gastrointestinal stromal tumors
Journal of surgical oncologyA Modified Floxuridine Reduced-Dose Protocol for Patients with Unresectable Colorectal Liver Metastases Treated with Hepatic Arterial Infusion
Annals of surgical oncologyASO Author Reflections
Annals of surgical oncologyCirculating Neoplastic-Immune Hybrid Cells Are Biomarkers of Occult Metastasis and Treatment Response in Pancreatic Cancer
CancersClinician overconfidence in visual estimation of the posthepatectomy liver remnant volume
Surgery (United States)Expert Commentary on Hepatic Artery Infusion Pump Chemotherapy for Colorectal Liver Metastases
Diseases of the colon and rectumExploratory Analyses of Circulating Neoplastic-Immune Hybrid Cells as Prognostic Biomarkers in Advanced Intrahepatic Cholangiocarcinoma
International journal of molecular sciencesLiver-First Resection in Patients With Synchronous Colorectal Liver Metastases Is Associated with Inferior Recurrence-Free Survival
Diseases of the colon and rectumOutcomes of Late-Line Systemic Treatment in GIST
CancersSafety and Effectiveness of Portal Vein Embolization after Hepatic Arterial Infusion Therapy
Journal of Vascular and Interventional RadiologyCurrent Practices in Hepatic Artery Infusion (HAI) Chemotherapy
Annals of surgical oncologyHepatectomy is associated with improved oncologic outcomes in recurrent colorectal liver metastases
Surgery (United States)Neoadjuvant therapy does not impact the biliary microbiome in patients with pancreatic cancer
Journal of surgical oncologyPhase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma
Cancer medicineSocioeconomic and Geographic Disparities in the Referral and Treatment of Pancreatic Cancer at High-Volume Centers
JAMA SurgeryThe genomics of liver metastases from colon and rectal cancer
Surgery (United States)Complications in Distal Pancreatectomy versus Radical Antegrade Modular Pancreatosplenectomy
World journal of surgeryConsiderations and barriers to starting a new HAI pump program
HPBEarly Versus Late Recurrence in Rectal Cancer
Journal of Gastrointestinal SurgeryHepatic arterial infusion pump chemotherapy combined with systemic therapy for patients with advanced colorectal liver metastases
Journal of surgical oncologyHepatic metastases in gastrointestinal stromal tumors
HPBIntensive care unit observation after pancreatectomy
Journal of surgical oncology